The new Body Scan 2 scale from Withings, unveiled at CES 2026, is set to revolutionize at-home health monitoring by detecting various heart conditions, including hypertension risks. This innovative device combines a traditional floor scale with a retractable handle, allowing users to evaluate over 60 biomarkers in approximately 90 seconds.
Among its groundbreaking features is the ability to assess hypertension risk without a cuff, utilizing an advanced AI model to identify arterial hypertension. Another notable capability is the detection of glycemic dysregulation, offering early warnings for conditions like prediabetes. Additionally, the scale introduces Impedance Cardiography (ICG) to monitor heart function and blood flow.
Withings emphasizes that many of these features are clinically validated, aiming to help users adopt healthier lifestyles. The scale will also provide a “Health Trajectory score,” illustrating how lifestyle changes can enhance long-term health. Priced at $599, which is $100 more than its predecessor, the Body Scan 2 is expected to launch in Q2 2026 and will sync via Wi-Fi or Bluetooth with other health apps.